Pharma Co. Challenges FDA's 'Uneven' Blood Drug Standards
By Jasmin Boyce ( September 14, 2022, 6:48 PM EDT) -- The maker of blood treatment Fibryga hit the U.S. Food and Drug Administration with a suit on Wednesday in D.C. federal court over what it says are the agency's "sharply uneven" standards for blood medications, arguing it was subjected to multimillion-dollar clinical trials while competitors were allowed to skip the "critical step."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.